OnKure Therapeutics, Inc. (NASDAQ:OKUR) Receives Average Rating of “Hold” from Analysts

Shares of OnKure Therapeutics, Inc. (NASDAQ:OKUR) have been given an average recommendation of “Hold” by the four brokerages that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $34.00.

A number of equities analysts recently commented on OKUR shares. Wall Street Zen upgraded OnKure Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of OnKure Therapeutics in a research note on Monday, December 22nd.

OnKure Therapeutics Trading Up 7.4%

OKUR opened at $3.78 on Friday. The stock has a fifty day moving average price of $2.84 and a 200 day moving average price of $2.87. OnKure Therapeutics has a 1 year low of $1.70 and a 1 year high of $5.28. The stock has a market cap of $51.22 million, a price-to-earnings ratio of -0.86 and a beta of 0.45.

OnKure Therapeutics (NASDAQ:OKUR) last posted its quarterly earnings results on Monday, March 9th. The company reported ($0.99) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.16. As a group, sell-side analysts forecast that OnKure Therapeutics will post -4.05 earnings per share for the current fiscal year.

Institutional Investors Weigh In On OnKure Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of OKUR. XTX Topco Ltd acquired a new position in OnKure Therapeutics during the second quarter worth $25,000. Bailard Inc. acquired a new stake in shares of OnKure Therapeutics in the second quarter worth about $34,000. Jane Street Group LLC acquired a new stake in shares of OnKure Therapeutics in the fourth quarter worth about $56,000. Barclays PLC boosted its stake in shares of OnKure Therapeutics by 4,286.8% during the 4th quarter. Barclays PLC now owns 27,242 shares of the company’s stock worth $79,000 after acquiring an additional 26,621 shares in the last quarter. Finally, Rangeley Capital LLC bought a new stake in shares of OnKure Therapeutics during the 2nd quarter worth about $71,000. Institutional investors and hedge funds own 90.98% of the company’s stock.

About OnKure Therapeutics

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.